OOIR: Observatory of International Research

Papers

(The TQCC of Lancet Infectious Diseases is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)

Article	Citations
Transaminases and serum albumin as early predictors of severe dengue – Authors' reply	1686
Environment and infectious diseases	1262
A step forward in the journey towards hookworm vaccines	909
Listeria monocytogenes: a rare, deadly cause of peritonitis	806
Surge of cutaneous leishmaniasis in Pakistan	673
Is ceftriaxone similarly effective to benzylpenicillin in neurosyphilis? – Authors' reply	600
Research in brief	595
Research in brief	521
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting	477
Role of the G20 in safe reopening of international travel	379
Attention to skin-related neglected tropical diseases	376
Infectious disease surveillance update	370
Chronicling PEPFAR's work in Africa	357
Ordinary people in extraordinary times	321
Infectious disease surveillance update	288
Rajendra Kapila	281
Promoting diversity and equity in publishing	280
Entering a labyrinth of COVID-19 stories	277
Correction to Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7	269
Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study	266
Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study	259
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial	258
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b tria	254
SARS-CoV-2 incidence and vaccine escape	244
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim–sulfamethoxazole in Germany: a phase 2/3, prospect	242

Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations	236
Mpox in people with past infection or a complete vaccination course: a global case series	234
Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1	224
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study	222
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-inco	219
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges	217
Adaora “Ada” Alise Adimora	216
The superiority of bivalent over monovalent booster vaccines	210
Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum	206
DNDi receives Dutch funding boost	205
COVID-19 vaccination protects children and adolescents	203
Can the USA return to pre-COVID-19 normal by July 4?	201
Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study	190
Reflecting on lessons from the 2014–16 Ebola virus outbreak	189
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis	182
Bold measures to accelerate malaria elimination	182
A patient with secondary syphilis following incomplete treatment of primary infection	171
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations	166
HIV vaccine trial failure	165
Threat of HIV and tuberculosis drug resistance after US funding cuts	163
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial	162
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic	162
The interplay between COVID-19 restrictions and vaccination	161
Updated criteria for paediatric sepsis and septic shock	161
Transitioning to endemicity with COVID-19 research	160
Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines	159
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial	157
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial	156
Neuropathology, pathomechanism, and transmission in zoonotic Borna disease virus 1 infection: a systematic review	156
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation	155
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden	155
The next chapter for Africa's genomic initiatives	154
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study	153
Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis	148
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the C	146
The importance of understanding the infectious microenvironment	145
Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in Côte d'Ivoire, Laos, and Pemba Island, Tanzania: a double-blin	143
Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2	142
Supporting healthcare access for refugees and migrants	141
History and evolution of tuberculosis and global health	140
Assessment of experimental malaria vaccine induced protection in pre-exposed populations	139
The implications of mpox breakthrough infections on future vaccination strategies	139
Election of Regional Director for the Western Pacific	139
High-dose primaquine reduces vivax relapses: time for change	138
Sizing the reservoirs of malaria transmission: the contribution of school-aged children	135
Severe influenza: is there a role for antiviral combinations?	135
Correction to Lancet Infect Dis 2021; 21: 962–74	131
Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world	130
Emil Gotschlich	130
Pre-emptively tackling vaccine misinformation for a successful large-scale roll-out of malaria vaccines in Africa	129

Immune evasiveness of SARS-CoV-2 variants and vaccine selection	129
Interplay of infection and vaccination in long-term protection from COVID-19	129
Global cholera resurgence—a preventable tragedy	128
First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis	128
The global burden of cryptococcosis—a neglected tropical disease?	128
Elisabeth Presterl—always looking forward	127
Assessing the burden of congenital rubella syndrome in China and evaluating mitigation strategies: a metapopulation modelling study	124
Super-spreaders: a historical review	124
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant	122
Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis	122
BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents	121
Addressing the shortage of cholera vaccines	118
Correction to Lancet Infect Dis 2023; 23: e469	117
Malaria vaccine development in Mali: a step towards transmission-blocking strategies	117
Allergic bronchopulmonary aspergillosis with chest pain as atypical symptoms	117
Correction to Lancet Infect Dis 2024; published online Feb 1. https://doi.org/10.1016/S1473-3099(23)00706-5	116
Correction to Lancet Infect Dis 2022; published online Aug 31. https://doi.org/10.1016/S1473-3099(22)00434-0	115
Correction to Lancet Infect Dis 2021; 21: 629–36	114
Research in brief	113
Full-dose NSAIDs at the first sign of respiratory infection?	113
Theresa Ochoa—staying on top of infectious diseases in Peru	110
Infectious disease surveillance update	108
Tuberculosis recovery in Georgia: implementing more by 24	106
Is combination antiviral therapy for influenza the optimal approach?	106
Curing chronic hepatitis B virus infection	101
Vaccine and surveillance implications of dengue underdetection	100
Research in brief	100
Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86	99
RSV prevention: public health lessons from the southern hemisphere	98
The response of mpox-associated inflammatory syndrome to steroid therapy	97
WHO Pathogen X conference	96
Correction to Lancet Infect Dis 2025; 25: e47–58	95
Guidelines adherence as a major protective aspect to increase survival rate in patients with candidaemia in Europe	94
Research in brief	93
New flavours of tuberculosis treatment for children	91
COVID-19 mortality in Africa and Asia – Authors' reply	90
Serpiginous-like choroiditis in ocular tuberculosis	90
Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study	89
Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings?	88
12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine	88
Post-viral sequelae of COVID-19 and influenza	88
Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products—an update	87
Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance	87
An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia	86
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial	86
Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation	85
Evaluating H56:IC31 vaccine in tuberculosis recurrence prevention	85
Worrying lack of funding for tuberculosis	84
WHO's first global infection prevention and control report	84
Twin threats: climate change and zoonoses	84
We need estimates of gonorrhoea vaccine protection and symptomaticity by sex and anatomical site	83
Effect of change in vaccine schedule on pertussis epidemiology in France: a modelling and serological study	83
A decentralised point-of-care testing model to address inequities in the COVID-19 response	82
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape	81
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-	81
Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study	81
Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis	80
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study	80
Statistical concerns for meta-analysis of rare events and small sample sizes – Authors' reply	79
Amal Saif Al-Maani—fighting antimicrobial resistance	79
Vaccine pragmatism in the 21st century	79
Next-generation malaria subunit vaccines to reduce disease burden in African children	79
Correction to Lancet Infect Dis 2021; 21: 929–38	78
A step closer to elimination of meningococcal disease	77
Child-friendly rifapentine formulation is a game changer	77
Infectious disease surveillance update	77
Spreading awareness on lymphatic filariasis	77
Advancing integration: progress reported for skin NTDs	76
Correction to Lancet Infect Dis 2024; published online Dec 17. https://doi.org/10.1016/S1473-3099(24)00588-7	75
A tale of potential mpox reinfection	75
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial	74
Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3	74
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial	73
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study	73
Ivermectin for malaria control in mass drug administration programmes	72
Incidence and risk factors of tuberculosis among 420 854 household contacts of patients with tuberculosis in the 100 Million Brazilian Cohort (2004–18): a cohort study	72
Gender and geographical representation at infectious diseases and clinical microbiology conferences	72
Cross-protective potential of a MF59-adjuvanted quadrivalent influenza vaccine in older adults	71
Highlights from ECCMID 2022	71
Clindamycin-resistant Streptococcus pyogenes in Chinese children	70

Correction to Lancet Infect Dis 2023; 23: e259–65	70
Correction to Lancet Infect Dis 2023; published online Aug 3. https://doi.org/10.1016/S1473-3099(23)00344-4	70
The urgent need to scale-up fungal diagnostics in Africa	69
Is the end of gonorrhoea in sight?	68
Pui-Ying Iroh Tam	68
On the frontline during the COVID-19 pandemic	68
Lessons learnt from conducting a randomised clinical trial in eumycetoma	68
Sir Michael Anthony Epstein	68
Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil	67
Eligibility of patients with Staphylococcus aureus bacteraemia for early oral switch	67
Research in brief	67
Moxidectin versus ivermectin for strongyloidiasis control	67
COVID-19 mortality in Africa and Asia	66
Sleeping sickness: time for dreaming	66
Prevention of non-ventilator-associated hospital-acquired pneumonia in Switzerland: a type 2 hybrid effectiveness–implementation trial	66
The origin of SARS-CoV-2 variants of concern	66
Social workers and neglected tropical diseases	66
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis	65
Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices	65
Human ocular thelaziosis—a zoonosis of the eye	65
Need for inclusion of high-risk populations and standardisation of immunogenicity outcomes in adult pneumococcal vaccine trials	64
SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster	64
Effectiveness of pyriproxyfen-pyrethroid and chlorfenapyr-pyrethroid long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs for malaria control in the third year post-distribution:	64
Access to flucytosine for the treatment of HIV-associated cryptococcal meningitis in Africa	64
Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study	64
Lassa fever research priorities: towards effective medical countermeasures by the end of the decade	63
Effect of mass campaigns with full and fractional doses of pneumococcal conjugate vaccine (Pneumosil) on the reduction of nasopharyngeal pneumococcal carriage in Niger: a three-arm, open-label, cluste	63
RH5.1/Matrix-M: highlighting blood-stage malaria vaccines	63
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial	63
Imprinted hybrid immunity against XBB reinfection	63
Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings	63
The spatiotemporal ecology of Oropouche virus across Latin America: a multidisciplinary, laboratory-based, modelling study	63
National case series of group A streptococcus pleural empyema in children: clinical and microbiological features	62
Re-emergence of Oropouche virus in Brazil and Latin America	62
Community-based mpox and sexually transmitted disease surveillance using discarded condoms in the global south	62
Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study	62
Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study	61
DoxyPEP: thinking towards implementation	61
Hong Kong's fifth COVID-19 wave—the worst yet	61
Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows	61
doxyPEP: a controversial new tool against STIs	61
Lien Jih-ching	60
Experts react to SAGO's preliminary report	60
Detective doctor decodes AIDS mystery	60
Outbreaks compound Brazil's flooding disaster	60
Correction to Lancet Infect Dis 2021; 21: 677–87	60
Correction to Lancet Infect Dis 2023; 23: 789	59
Monkeypox trial to begin in DR Congo	59
Infectious disease surveillance update	59
Antibody durability at 1 year after Sputnik V vaccination	58
Antibiotic stewardship in the real world	58
A vanquished threat or a cautionary tale?	57
Randomised controlled trials for mpox in endemic countries	57
Zika vaccines: can we solve one problem without creating another one?	57
Alexandra King—promoting Indigenous self-determination	57
Understanding the immunogenicity of RTS,S in infants	56
Correction to Lancet Infect Dis 2025; 25: e11–12	56
Lessons from the English primary care sentinel network's response to the COVID-19 pandemic	55
Developing the EAVE III platform for future health crises	55
Transmissibility of SARS-CoV-2 among fully vaccinated individuals	54
Correction to Lancet Infect Dis 2022; published online Jan 25. https://doi.org/10.1016/S1473-3099(21)00586-7	54
A step forward for Plasmodium falciparum malaria transmission-blocking vaccines	54
A shared history	54
Learning and confirming in publicly funded antiviral trials	53
Deaths of unknown cause in DR Congo	53
A new formulation of praziquantel to achieve schistosomiasis elimination	53
Effect of single-dose, live, attenuated dengue vaccine in children with or without previous dengue on risk of subsequent, virologically confirmed dengue in Cebu, the Philippines: a longitudinal, prosp	53
Humanitarian crisis in Tigray amidst civil war	53
Disseminated Mycoplasma pneumoniae infection presenting with polyarthritis and endocarditis	53
Sleeper frameworks for Pathogen X: surveillance, risk stratification, and the effectiveness and safety of therapeutic interventions	52
Mpox control strategies: using behaviour change to complement, not replace, vaccination	52
Global measles cases up 20% in 2023	51
What is the pandemic potential of avian influenza A(H5N1)?	51
Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation	51
Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia	50
Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study	50
Understanding vancomycin nephrotoxicity augmented by β-lactams: a synthesis of endosymbiosis, proximal renal tubule mitochondrial metabolism, and β-lactam chemistry	50
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden	50
Salmonella Typhimurium outbreak linked to chocolate	50
Successful use of interferon alfa-2a for persistent parvovirus B19 infection	49
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-base	49
A new key-player for onchocerciasis elimination	49
What chikungunya teaches us about COVID-19	49
Impact of COVID-19 on migrants and refugees	48
Struggling with a new dengue epidemic in Nepal	47
Reporting of deaths during cholera outbreaks: case fatality ratio and community deaths	47
Artificial intelligence to transform public health in Africa	47
Correction to Lancet Infect Dis 2025; published online Feb 13. https://doi.org/10.1016/S1473-3099(24)00749-7	46
COVID-19 versus influenza: the need to align policies with COVID-19 realities	46
H5N1 avian influenza: tracking outbreaks with real-time epidemiological data	46
Revisiting oral antivirals for COVID-19 in the hospital setting	46
Correction to Lancet Infect Dis 2024; published online Feb 9. https://doi.org/10.1016/S1473-3099(23)00731-4	46
Antiblackness in the Ebola response in Sierra Leone	46
Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021–22: a descriptive epidemiological study	45
The global alarm bell is ringing due to the threat of potential severe cases and deaths caused by clade I of monkeypox virus	45